Amarjot Kaur
Research Subjects
Amarjot Kaur has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Harold Kim
Department of Medicine, McMaster University, Hamilton, Canada
2 shared publications - Harold S. Nelson
National Jewish Health, Denver, Colo
2 shared publications - Hendrik Nolte
Merck & Co, Kenilworth, NJ
2 shared publications - Jacques Hébert
Centre de Recherche Appliquée en Allergie de Québec, Québec, Canada
2 shared publications - Jennifer Maloney
Merck & Co., Inc., Whitehouse Station, NJ USA
2 shared publications - Michael S. Blaiss
Medical College of Georgia Augusta University Augusta Georgia USA
2 shared publications
Latest Publications
- Open Access
- 10 November 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 55
Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis
Currently accepted therapies for ragweed allergy in North America consist of pharmacotherapy and subcutaneous allergen immunotherapy injections to treat symptoms. Allergen immunotherapy not only reduces symptoms and the need for pharmacotherapy but has also been shown to have disease-modifying potential. Recently, ragweed immunotherapy administered via sublingual allergen tablet has been approved in North America for treatment of allergic rhinitis with and without conjunctivitis.
- 10 November 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 55
Open AccessEfficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis
Currently accepted therapies for ragweed allergy in North America consist of pharmacotherapy and subcutaneous allergen immunotherapy injections to treat symptoms. Allergen immunotherapy not only reduces symptoms and the need for pharmacotherapy but has also been shown to have disease-modifying potential. Recently, ragweed immunotherapy administered via sublingual allergen tablet has been approved in North America for treatment of allergic rhinitis with and without conjunctivitis.
- Open Access
- 30 October 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 53
The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children
The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians.
- 30 October 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 53
Open AccessThe efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children
The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians.